Pages that link to "Q83861488"
Jump to navigation
Jump to search
The following pages link to Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trial (Q83861488):
Displaying 8 items.
- Small Molecule Modulators of Keap1‐Nrf2‐ARE Pathway as Potential Preventive and Therapeutic Agents (Q28386244) (← links)
- Current status of novel antifibrotic therapies in patients with chronic liver disease (Q30473375) (← links)
- Hepatic inflammation and progressive liver fibrosis in chronic liver disease (Q37629675) (← links)
- Control of Oxidative Posttranslational Cysteine Modifications: From Intricate Chemistry to Widespread Biological and Medical Applications (Q37959529) (← links)
- Targeting Hepatic Fibrosis in Autoimmune Hepatitis. (Q38902371) (← links)
- Antifibrotics in chronic liver disease: tractable targets and translational challenges (Q39238770) (← links)
- Nrf2 at the Heart of Oxidative Stress and Cardiac Protection (Q47350229) (← links)
- Nrf2 activation ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain (Q90589209) (← links)